Tags

Type your tag names separated by a space and hit enter

Treatment of selected pharmaceuticals by ferrate(VI): performance, kinetic studies and identification of oxidation products.
J Pharm Biomed Anal. 2015 Mar 15; 106:37-45.JP

Abstract

The performance of ferrate(VI) in treating sulfamethoxazole (SMX), diclofenac (DCF), carbamazepine (CBZ) and bezafibrate (BZF) in test solutions containing the four compounds was investigated. A series of jar-test experiments was performed on a bench-scale at pH 6-9 and at a ferrate(VI) dose of 1-5 mg Fe/L. The results suggested that ferrate(VI) can effectively remove SMX, DCF and CBZ from the test solutions, with greater than 80% removal under optimum conditions. However, the removal efficiency of BZF was very low, less than 25% under the studied conditions. Increasing the dose of ferrate(VI) improved the treatment performance, while the influence of solution pH on ferrate(VI) performance varied among the different target compounds. Ferrate(VI) demonstrated the highest reactivity with SMX at pH 8 and pH 9 (20 °C), with apparent second-order rate constants of 360±17 M(-1) s(-1) and 1.26±0.02 M(-1) s(-1), respectively. However, BZF showed the lowest removal by ferrate(VI) with the smallest rate constants (less than 0.5 M(-1) s(-1)) at pH 8 and pH 9. Furthermore, a number of oxidation products (OPs) of SMX, DCF and CBZ during ferrate(VI) oxidation were detected by liquid chromatography and mass spectrometry (LC-MS), and their degradation pathways were tentatively proposed. No OPs of BZF were detected during ferrate(VI) oxidation.

Authors+Show Affiliations

School of Engineering and Built Environment, Glasgow Caledonian University, Glasgow G4 0BA, Scotland, United Kingdom.School of Engineering and Built Environment, Glasgow Caledonian University, Glasgow G4 0BA, Scotland, United Kingdom. Electronic address: jiaqian.jiang@gcu.ac.uk.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25063450

Citation

Zhou, Zhengwei, and Jia-Qian Jiang. "Treatment of Selected Pharmaceuticals By ferrate(VI): Performance, Kinetic Studies and Identification of Oxidation Products." Journal of Pharmaceutical and Biomedical Analysis, vol. 106, 2015, pp. 37-45.
Zhou Z, Jiang JQ. Treatment of selected pharmaceuticals by ferrate(VI): performance, kinetic studies and identification of oxidation products. J Pharm Biomed Anal. 2015;106:37-45.
Zhou, Z., & Jiang, J. Q. (2015). Treatment of selected pharmaceuticals by ferrate(VI): performance, kinetic studies and identification of oxidation products. Journal of Pharmaceutical and Biomedical Analysis, 106, 37-45. https://doi.org/10.1016/j.jpba.2014.06.032
Zhou Z, Jiang JQ. Treatment of Selected Pharmaceuticals By ferrate(VI): Performance, Kinetic Studies and Identification of Oxidation Products. J Pharm Biomed Anal. 2015 Mar 15;106:37-45. PubMed PMID: 25063450.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Treatment of selected pharmaceuticals by ferrate(VI): performance, kinetic studies and identification of oxidation products. AU - Zhou,Zhengwei, AU - Jiang,Jia-Qian, Y1 - 2014/07/01/ PY - 2014/03/19/received PY - 2014/06/22/revised PY - 2014/06/23/accepted PY - 2014/7/27/entrez PY - 2014/7/27/pubmed PY - 2016/3/11/medline KW - Ferrate(VI) KW - Oxidation products (OP) KW - Pharmaceuticals KW - Rate constants KW - Waste water treatment SP - 37 EP - 45 JF - Journal of pharmaceutical and biomedical analysis JO - J Pharm Biomed Anal VL - 106 N2 - The performance of ferrate(VI) in treating sulfamethoxazole (SMX), diclofenac (DCF), carbamazepine (CBZ) and bezafibrate (BZF) in test solutions containing the four compounds was investigated. A series of jar-test experiments was performed on a bench-scale at pH 6-9 and at a ferrate(VI) dose of 1-5 mg Fe/L. The results suggested that ferrate(VI) can effectively remove SMX, DCF and CBZ from the test solutions, with greater than 80% removal under optimum conditions. However, the removal efficiency of BZF was very low, less than 25% under the studied conditions. Increasing the dose of ferrate(VI) improved the treatment performance, while the influence of solution pH on ferrate(VI) performance varied among the different target compounds. Ferrate(VI) demonstrated the highest reactivity with SMX at pH 8 and pH 9 (20 °C), with apparent second-order rate constants of 360±17 M(-1) s(-1) and 1.26±0.02 M(-1) s(-1), respectively. However, BZF showed the lowest removal by ferrate(VI) with the smallest rate constants (less than 0.5 M(-1) s(-1)) at pH 8 and pH 9. Furthermore, a number of oxidation products (OPs) of SMX, DCF and CBZ during ferrate(VI) oxidation were detected by liquid chromatography and mass spectrometry (LC-MS), and their degradation pathways were tentatively proposed. No OPs of BZF were detected during ferrate(VI) oxidation. SN - 1873-264X UR - https://www.unboundmedicine.com/medline/citation/25063450/Treatment_of_selected_pharmaceuticals_by_ferrate_VI_:_performance_kinetic_studies_and_identification_of_oxidation_products_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0731-7085(14)00320-3 DB - PRIME DP - Unbound Medicine ER -